公开(公告)号：US20150191542A1

公开(公告)日：2015-07-09

申请号：US14377274

申请日：2013-02-07

Applicant: INNATE PHARMA, S.A.

Inventor： Mathieu Blery ,  Laurent Gauthier ,  Ivan Perrot ,  Cecile Bonnafous

IPC: C07K16/28 ,  G01N33/569

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K16/2833 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56977 ,  G01N2333/70539

Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.

Abstract translation: 本发明涉及使用特异性结合MICA的抗体，抗体片段及其衍生物治疗由MICA表达细胞介导的病症的方法。 本发明还涉及抗体; 产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 和包含其的药物组合物。

公开(公告)号：US20150140000A1

公开(公告)日：2015-05-21

申请号：US14403171

申请日：2013-05-30

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Laurent Gauthier ,  Yannis Morel ,  Carine Paturel ,  Ivan Perrot

IPC: C07K16/28 ,  A61K47/48

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.

Abstract translation: 本文公开了抗TLR3抗体以及制备和使用它们的方法。 抗体特别适用于使用抗TLR3抗体治疗自身免疫性或炎性疾病。

公开(公告)号：US12252543B2

公开(公告)日：2025-03-18

申请号：US16173150

申请日：2018-10-29

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07H21/00 ,  A61K39/00 ,  C07K16/28 ,  C12N15/86 ,  C12N5/0783

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US12202907B2

公开(公告)日：2025-01-21

申请号：US17855510

申请日：2022-06-30

Applicant: Innate Pharma ,  Orega Biotech

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US11958907B2

公开(公告)日：2024-04-16

申请号：US17009817

申请日：2020-09-02

Applicant: INNATE PHARMA

Inventor： Ivan Perrot ,  Carine Paturel ,  Laurent Gauthier

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2896 ,  C07K16/30 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

公开(公告)号：US11692039B2

公开(公告)日：2023-07-04

申请号：US17566142

申请日：2021-12-30

Applicant: INNATE PHARMA ,  SANOFI

Inventor： Marielle Chiron ,  Angela Virone-Oddos ,  Laurent Gauthier

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/02 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K39/395 ,  A61K39/3955 ,  A61P35/02 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/64

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).

公开(公告)号：US11377492B2

公开(公告)日：2022-07-05

申请号：US16478863

申请日：2018-01-22

Applicant: INNATE PHARMA

Inventor： Nadia Anceriz ,  Mathieu Blery ,  Laurent Gauthier ,  Carine Paturel

IPC: C07K16/30 ,  A61P35/00 ,  C07K16/28 ,  A61K47/68 ,  G01N33/569

Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.

公开(公告)号：US20200299380A1

公开(公告)日：2020-09-24

申请号：US16804705

申请日：2020-02-28

Applicant: Innate Pharma

Inventor： Mathieu Blery ,  Laurent Gauthier ,  Ivan Perrot ,  Cecile Bonnafous

IPC: C07K16/28 ,  G01N33/569

Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.

公开(公告)号：US10434180B2

公开(公告)日：2019-10-08

申请号：US15214331

申请日：2016-07-19

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Laurent Gauthier ,  François Romagne ,  Eliane Fischer ,  Roger Schibli

IPC: A61K31/5517 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/50 ,  C12N9/10 ,  C12P21/00 ,  G01N33/68 ,  A61K47/48 ,  A61K47/68

Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

公开(公告)号：US10132799B2

公开(公告)日：2018-11-20

申请号：US14414432

申请日：2013-07-10

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Christian Belmant ,  Delphine Bregeon ,  Patrick Dennler ,  Eliane Fischer ,  François Romagne ,  Roger Schibli ,  Laurent Gauthier

IPC: A61K47/48 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  A61K31/5517 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/50 ,  C12N9/10 ,  C12P21/00 ,  G01N33/68 ,  G01N33/532 ,  G01N33/50 ,  A61K47/68

Abstract: Provided is a method for the functionalization of immunoglobulins through the use of transglutaminase, including methods for screening functionalized antibodies for characteristics of interest, antibody compositions comprising a plurality of functionalized antibodies, and functionalized antibodies with rodent constant regions.